



Contacts:

Justin Emily Wills
Fleishman-Hillard
816-512-2387
justin.wills@fleishman.com

Carlos Casas
Fleishman-Hillard
816-512-2344
carlos.casas@fleishman.com

CIVIC VOLUNTEER ADVOCATES FOR PARKINSON'S

Mike O'Leary uses words, actions to support Parkinson's patients

Phoenix, Ariz. (Jan. 22, 2008) — Mike O'Leary knows what it's like to live with Parkinson's disease (PD) day in and day out. He describes it as "feeling like being trapped inside a body that doesn't work, and you can't get out." But through his volunteer efforts in such organizations as the Parkinson Disease Foundation, and the Muhammad Ali Parkinson's Center, O'Leary is helping himself and other PD patients find their way.

For two years, O'Leary noticed leg tremors, limited arm movement and a dwindling sense of smell. Listening to a radio show about Michael J. Fox confirmed his fears. O'Leary was diagnosed with PD in January 2002. Upon hearing the news, he felt lost, not knowing what to do next.

Over the next five years, O'Leary juggled his PD symptoms and depression. He felt temporary relief, at times. Other times his symptoms would get the best of him. He'd stumble just because his leg would not be able to pick up his foot. Working at a nuclear power plant as a controller was no longer possible. Eventually O'Leary had to leave his job and go on long-term disability.

During a visit with his neurologist in 2007, O'Leary received AZILECT[®] (rasagiline tablets). AZILECT is a once-daily oral tablet approved by the FDA in 2006 to treat the signs and symptoms of Parkinson's disease as initial monotherapy and as add-on therapy to levodopa. Although individual results may vary, within just weeks, he noticed an improvement in his symptoms. "Now my arm swings and things like going to the gym or a restaurant are not as challenging," O'Leary said.

Since being diagnosed, O'Leary focuses his time on leading support groups and organizing conferences that help newly-diagnosed PD patients. He is often a voice for PD in front of Congress, urging decision-makers to create more funds for PD research.

— more —

Additionally, he works with the Parkinson Disease Foundation's People with Parkinson Advisory Council, which was formed to give patients a voice in the decision-making process at the foundation. His efforts won him the Louis Fishman Advocacy Award, a special recognition given by the Parkinson's Action Network. O'Leary was also nominated as a finalist in the 2004 Arizona Cardinals NFL Community Quarterback Program for his volunteer efforts.

"PD is not a death sentence," he said. "We have an opportunity to take charge. Let's meet this disease head on and beat it."

O'Leary lives in Tempe with his wife, who also has PD. He and his wife met three years ago at a PD conference, and they have three daughters, ages 17, 20, and 26 and two sons, ages 22 and 28. O'Leary is currently helping organize a jazz festival in Phoenix to raise funds for PD research.

About AZILECT®

AZILECT® (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease. The effectiveness of AZILECT was shown in patients with early PD who were receiving AZILECT as initial therapy alone and who were not receiving any other PD therapy. The effectiveness of AZILECT as adjunct therapy was shown in patients with PD who were treated with levodopa.

Important Safety Information:

- Patients should not take AZILECT if they are currently taking meperidine as it could possibly result in a serious reaction such as coma or death.
- Patients should not take AZILECT with tramadol, methadone, propoxyphene, dextromethorphan, St. John's wort, mirtazapine, or cyclobenzaprine.
- Patients should not take AZILECT with other monoamine oxidase inhibitors (MAOIs), amphetamines, cold remedies containing decongestants and weight-reducing preparations containing pseudoephedrine, phenylephrine, phenylpropanolamine, or ephedrine in order to avoid a possibly dangerous increase in blood pressure. Symptoms of this reaction include severe headache, blurred vision, difficulty thinking, seizures, chest pain, unexplained nausea or vomiting, or signs or symptoms of a stroke. Patients or caregivers should seek immediate medical attention if these symptoms or other unusual symptoms occur.
- **In order to prevent a possibly dangerous increase in blood pressure, patients taking AZILECT should avoid foods and beverages high in tyramine content such as aged cheeses, air-dried meats, pickled herring, yeast extract, aged red wines, tap/draft beers, sauerkraut, and soy sauce.**
- Patients taking AZILECT should not have elective surgery requiring general anesthesia, and should not receive cocaine or other local anesthesia that contains ingredients that could raise blood pressure.

- Patients should inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin.
- Patients with moderate to severe liver disease or a tumor of the adrenal gland should not take AZILECT[®] (rasagiline tablets).
- All PD patients are advised to monitor for melanoma (skin cancer) frequently and see a dermatologist on a regular basis.

Side effects seen with AZILECT alone are headache, joint pain and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesias), accidental injury, nausea, weight loss, constipation, low blood pressure when standing, joint pain, vomiting, dry mouth, rash, and sleepiness. Patients should tell their doctor about these and any other side effects they experience when taking AZILECT.

About Parkinson's Disease

Parkinson's disease is an age-related degenerative disorder of the brain. Symptoms can include tremor, stiffness, slowness of movement, and impaired balance. An estimated one million Americans have the disease, which usually affects people over the age of 60.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world. The company develops, manufactures, and markets innovative and generic human pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

Teva's U.S. innovative product marketing subsidiary, Teva Neuroscience, Inc., promotes AZILECT[®] (rasagiline tablets) in the United States. AZILECT is a registered trademark of Teva Pharmaceutical Industries Ltd. Please visit www.AZILECT.com for additional important information.

***Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:** This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra[®] and Neurontin[®], the effects of competition on our innovative products, especially Copaxone[®] sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration,*

European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results through our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Please see enclosed additional important information.

###

07292609/071668